Post Content
Avantor, Inc. (NYSE:AVTR) is one of the 10 Best Medical Stocks to Buy Under $30. On April 1, William Blair reaffirmed its Market Perform rating on Avantor, Inc. (NYSE:AVTR) after the company announced the departure of its Chief Financial Officer, Brent Jones.
Jones will leave Avantor, Inc. (NYSE:AVTR) on or before June 24. Despite this leadership change, the company has maintained its 2026 guidance. This update comes after the company had cut its guidance twice in 2025 and an initial 2026 forecast that was below market expectations. William Blair pointed out that even with a volatile quarter, the company seems to be moving towards its full-year targets.
The CFO transition follows a recent change in the CEO position and the launch of Avantor, Inc.’s (NYSE:AVTR) Revival turnaround program. This program builds on earlier cost-cutting efforts that Jones had led.
William Blair also noted that the CFO departure was not a complete surprise, pointing out that roughly three-fourths of the companies in its coverage universe have experienced at least one CFO change in recent years.
Avantor, Inc. (NYSE:AVTR) is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. It serves as an important partner in research, development, and production in the medicine, healthcare, and technology markets.
While we acknowledge the potential of AVTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Fintech Stocks to Invest In According to Billionaires and 10 Unrivaled Stocks of the Next 5 Years.
Disclosure: None. Follow Insider Monkey on Google News.